Completed PHASE2 INTERVENTIONAL 1-arm NCT03053544

Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer

Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer: An Internal Pilot Study

Sponsor: Sunnybrook Health Sciences Centre

Conditions Rectal Neoplasm Carcinoma in Situ Adenocarcinoma

Interventions Metformin

Updated 8 times since 2017 Last updated: Sep 25, 2019 Started: Dec 8, 2016 Primary completion: Jun 26, 2019 Completion: Jun 26, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Rectal Neoplasm Carcinoma in Situ Adenocarcinoma and is currently completed. Sunnybrook Health Sciences Centre leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
May 2019 — Oct 2019 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 3 earlier versions

Jun 2018 — May 2019 [monthly]

Recruiting PHASE2
May 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Feb 2017 — May 2017 [monthly]

Recruiting PHASE2

First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sunnybrook Health Sciences Centre
Sunnybrook Research Institute
University of Toronto

Data source: Sunnybrook Health Sciences Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada